How to Measure Outcomes in Disease Management

May 2008 Al Lewis Disease Management Purchasing Consortium

www.dismgmt.com

All slides © 2008 DMPC

DMPC Disease Management Purchasing Consortium Advisory Council

Agenda

- Who am I? Why am I here?
- Why your program results may not be valid
 - Back by popular demand, planes on the ground analogy
 - Examples of mistakes driven by pre-post
- How to Measure validly using utilization rates
 - Real world examples and interesting findings



Who am I? Why am I here?

 Invented disease management (according to Google) and founded DMAA



Who am I? Why am I here?

- Invented disease management (according to Google) and founded
 DMAA
- Have done more procurements than anyone on earth



Who am I? Why am I here?

- Invented disease management (according to Google) and founded DMAA
- Have done more procurements than anyone on earth
- Have Certified 30 payors for savings validity and 60 individuals as qualified to measure outcomes



Agenda

- Who am I? Why am I here?
- Why your program results may not be valid
 - Back by popular demand, planes on the ground analogy
 - Examples of mistakes driven by pre-post
- How to Measure validly using utilization rates
 - Real world examples and interesting findings



Current Situation

Show of hands time –agree or disagree:
– Is your reported ROI generally valid?



Why pre-post is not the best way to look at DM outcomes

- Watch what happens in the following analogy and then...
- ...Watch what happens in the following hypothetical using the exact pre-post methodology which you are being shown



Let's look at this by analogy to airplanes

- Assume at any given time:
 - 25% of planes are cruising at 20,000 feet
 - 25% of planes are ascending at 10,000 feet
 - 25% of planes are descending at 10,000 feet
 - (25% of planes are on the ground)



What is the average altitude in this example?

DMPC | Disease Management Purchasing Consortium Advisory Council

Assume at any given time

- 25% of planes are cruising at 20,000 feet
- 25% of planes are ascending at 10,000 feet
- 25% of planes are descending at 10,000 feet
- The average FLIGHT is at 13,333 feet



Assume at any given time

- 25% of planes are cruising at 20,000 feet
- 25% of planes are ascending at 10,000 feet
- 25% of planes are descending at 10,000 feet
- 25% of planes are on the ground
- The average FLIGHT is at 13,333 feet
- The average PLANE is at 10,000 feet

Further assume...

- 25% of planes are cruising at 20,000 feet
- 25% of planes are ascending at 10,000 feet
- 25% of planes are descending at 10,000 feet
- 25% of planes are on the ground
- The average FLIGHT is at 13,333 feet
- The average PLANE is at 10,000 feet
- Further assume that planes spend an hour (= one claims cycle) on the ground, ascending, descending, cruising

The Analogy between flights and claims

- 25% of planes are cruising at 20,000 feet
 These are High-claims members
- 25% of planes are ascending at 10,000 feet
 These are Low-claims members
- 25% of planes are descending at 10,000 feet
 These are Low-claims members
- 25% of planes are on the ground
 - These members have no claims for the disease in question

Here's where current methodologies start the baseline (first) tracking



The benefits consultant/DM vendor approach – moving from planes to claims

- Tracks ALL people with claims for the disease, high or low, in the baseline
- Emphasizes finding low utilizers for a population-based approach
 - Equivalent to finding all *flights* including ascending and descending
 - Average baseline altitude (2/3 at 10,000, 1/3 at 20,000) is: 13,333 feet

You measure the claims on ALL patients with claims

High claims (33%)







You measure the claims on ALL patients with claims

High claims (33%

Disease Management Purchasing Consortium Advisory Council





Why don't you measure these guys?



The conventional approach

- Tracks ALL claims with claims for the disease, high or low, in the baseline
 - Equivalent to finding all *flights*
 - Average baseline altitude (2/3 at 10,000, 1/3 at 20,000) is: 13,333 feet

Now, track the baseline flights an hour later (analogous to tracking the claims during the study period)

DMPC | Disease Management Purchasing Consortium Advisory Council



We can all agree that...

- The aviation system is in a steady state
- Still 25% at each point
- Average altitude has not changed









But wait...Some people say...

- "We don't track the people with no claims in the 'post' period in order to maintain equivalency with the 'pre' period"
- "The member has to re-trigger [with claims] each year to be counted" ("annual requalification")
 - So this bias shouldn't happen because we don't measure the zeros in EITHER period

"So this should happen because you don't measure the zeroes, right?"



Wrong

• What is the fallacy with that "adjustment"?



Explanation of why the bias is still there even if zeroes aren't measured

- Because AFTER a "plane on the ground" has an event and then recovers, that person is put on drugs (asthma, beta blockade, antihyperlidemics etc.)
 - And for some period of time they comply





The Fallacy

- If people were as likely to take drugs to prevent attacks *before* as *after*, then this adjustment would remove bias
- However, people are way more likely to take drugs (and hence have nonzero claims) after they land than before they take off

Many more people have zero identifiable claims before an event than after it

High claims





Pre-post would be valid if only...

- People were as likely to take preventive meds before an event as after it
- People had an implanted chip which notified the health plan as soon as they had a chronic disease even if they didn't incur claims to treat it



Why pre-post is not the best way to look at DM outcomes

- Watch what happens in the following analogy and then...
- ...Watch what happens in the following hypothetical using the exact pre-post methodology which you use



In this example

- Assume that "trend" is already taken into account correctly
- Focus on the baseline and contract period comparison



Base Case: Example from Asthma First asthmatic has a \$1000 IP claim in 2005

	2005 (baseline)	2006 (contract)
Asthmatic #1	1000	
Asthmatic #2		
Cost/asthmatic		



Example from Asthma Second asthmatic has an IP claim in 2006 while first asthmatic goes on drugs (common post-event)			
	2005 (baseline)	2006 (contract)	
Asthmatic #1	1000	100	
Asthmatic #2	0	1000 What is the	
Cost/asthmatic		Cost/asthmatic In the baseline?	

DISEASE Management Purchasing Consortium Advisory Council

Cost/asthmatic in baseline?

	2005 (baseline)	2006 (contract)
Asthmatic #1	1000	100
Asthmatic #2	0	1000
Cost/asthmatic	\$1000	Vendors don't count #2 in 2005 bec. he can't be found


Cost/asthmatic in contract period?

	2005 (baseline)	2006 (contract)
Asthmatic #1	1000	100
Asthmatic #2	0	1000
Cost/asthmatic	\$1000	\$550



••••••••••••••••••••••••••••••••••••••	Post Overstate	es Savings
	2005 (baseline)	2006 (contract)
Asthmatic #1	1000	100
Asthmatic #2	0	1000
Cost/asthmati c	\$1000	\$550

The Valid Way to Check Pre-Post Savings Claims

- You look at the event rates overall in the plan (or in your own organization if large enough) over time
 - As though you were measuring a birth rate. Very simple
 - As in this example, count total IP (and ER) events, divide by 1000



Asthma events in the payor as a whole — the plausibility check

	2005 (baseline)	2006 (contract)
Asthmatic #1	1000	100
Asthmatic #2	0	1000
Inpatient events/year	1	1

This is called a "plausibility check"

- You use plausibility checks all the time in your everyday life and don't think twice about them
 - But for some reason in DM people rely on faith instead



If you're still not convinced...

- Imagine applying a pre-post to a maternal program to measure outcomes
 - Find every woman who had a baby in the last two years (or underwent fertility or stopped filling BC bill prescriptions)
 - This is (for example) 10,000 babies last year and the year before

This cohort will account for about 5000 babies this year The "plausibility indicator" of counting babies yields 10,000 MPC Disease Management Purchasing Consortium Advisory Council

That little insight is what's missing from your reports

- Pre-post is only valid if confirmed with event rates...
- The question is, did you reduce events in the conditions in which you were trying to reduce events?
 - Otherwise where did the savings come from, if not from event reduction in the conditions the program was managing?

If you're still not convinced...

- Imagine applying a pre-post to a maternal program to measure outcomes
 - Find every woman who had a baby in the last two years (or underwent fertility or stopped filling BC bill prescriptions)
 - This is (for example) 10,000 babies last year and the year before



To sum up

- This is not "He said. She said." It's a math proof
 - "Everyone is entitled to their own opinions, but not to their own facts."
- The fundamental flaw in the "population-based pre-post" approach is that you cannot identify the whole population in advance, as in this example due to "planes on the ground."
 - It is not "population-based" at all but rather a special case of regression to the mean

Plausibility Analysis

- ALL ER and IP events primary-coded to a condition (see next slide) divided by all people in your employment
 - If you are <50,000 employees, make your health plan use Book of Business
- NOT people, just claims
- Write to me for the 16 watch-outs in compiling this simple metric (*e.g.*, what to do with transfers, admits at year-end etc.)

All based on this one table

Disease Program Category	ICD9s (all .xx unless otherwise indicated)
Asthma	493 (including 493.2x11)
Chronic Obstructive Pulmonary Disease	491.1, 491.2, 491.8, 491.9, 492, 494, 496, 506.4
Coronary Artery Disease (and related heart-health issues)	410, 411, 413, 414
Diabetes (CAD codes above will also indicate the success of the diabetes program)	250
Heart Failure	428, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 425.0, 425.4

1 493.2x is asthma with COPD. It could fit under either category but for simplicity we are keeping it with asthma



Agenda

- Who am I? Why am I here?
- Why your program results may not be valid
 - Back by popular demand, planes on the ground analogy
 - Examples of mistakes driven by pre-post
- How to Measure validly using utilization rates
 - Real world examples and interesting findings



Actual Report example – how to mislead with pre-post

Service category	Expected Cost (adjusted for trend)	Actual cost	Savings
Inpatient	\$137	\$131	\$6
ER	\$8.00	\$7.50	\$0.50
Outpatient	\$59	\$56	\$3
Labs	\$9.00	\$8.80	\$0.20
Office Visit	\$69	\$61	\$8
Drugs	\$131	\$127	\$4

How you know this is wrong

- Savings in areas which DM doesn't affect (labs)
- Savings in areas which should increase with DM (drugs, MD visits)
 - Any reduction is due to generic substitution or other effects not part of DM
- No disease-specific event rate "plausibility check" on ER and IP
 - We did an event rate check and there was no change



Example: Cigna Presentation on DM Outcomes How do you know this is wrong?			
Disease Category	All-cause Admission Reduction per disease member	All-cause Claims Cost Reduction per disease member	
Asthma	2%	12%	
cardiology	5%	15%	



How you know this is wrong

- Probably the admission reduction is wrong too but assume that it's right
- Hospital cost is only about half of total cost for a condition
 - Therefore total costs can fall only about half as fast as hospital costs. Certainly they cannot fall 3-5x faster
- Savings are shown in asthma, which is impossible with that level of admission reduction
 - See spreadsheet

If you are being shown savings in asthma your entire outcomes report (not just asthma) is invalid

- Assume:
 - \$0.25 PMPM for asthma alone (\$0.60 per contract holder)
 - \$2000/day inpatient and \$400/ER visit
 - Standard event rates and admission rates from ER
 - 2-day ALOS
 - Small reduction in comorbidities



It turns out that – and look at the spreadsheet – that...

- Spending on asthma ER and IP events is only a little higher than the cost of the program itself
 - IP and ER events would have to decline by 60%+ just to break even, assuming no increase in drug spending
 - You can see this for yourself on the spreadsheet



Agenda

- Who am I? Why am I here?
- Why your program results may not be valid
 - Back by popular demand, planes on the ground analogy
 - Examples of mistakes driven by pre-post
- How to Measure validly using utilization rates
 Real world examples and interesting findings



Real-world examples

- These are event rates by health plans over time
 - Note that a thin line is pre-DM, dotted is implementation, and thick line is post-DM
- Following DM, events would have to decline noticeably for the savings shown in a typical pre-post 2:1 ROI to be accurate



Historic trend in ER and IP rates, by condition, Northeast health plan



Implications

- Huge progress in asthma, which has been a major focus
- Note that blips up in recent years due to adding a municipality (they were supposed to not count them in the data but they did)
- Solid improvements in other conditions, taking the above comment into account



Some real-world examples

- These are event rates by health plans over time
 - Note that a thin line is pre-DM, dotted is implementation, and thick line is post-DM
- Following DM, events would have to decline noticeably for the savings shown in a typical pre-post 2:1 ROI to be accurate.
- It may be that the reason the improvements are modest is that the program is longstanding and has been successful for years even before DM, so that a plunge is unlikely

Example: total asthma events across plans





What did this slide show?

- Plan 5 has a very successful asthma program (assume that age profiles of these plans are similar)
- The other plans instituted asthma programs and failed to show actual savings despite giddy pre-post reports claiming ROIs.
- Even so, a "nexus" is needed between Plan 5 results and program

Example: total asthma events across plans – Plan 5 is best: WHY?





Plan 5: Do their practices support their results...or is it luck?

- Tight provider network
- Careful monitoring of use of evidence-based medicine
- Excellent disease management
 - Short "time to contact" between diagnosis and disease management
 - Disease mgmt at provider level too
- Urgent care center contracts prevent ER visits

ER/IP Usage --Incident Rate Per 1,000 Members CAD Rates





Heart Failure Fluid Overload

ER/IP Incident Rate Per 1,000 Members CHF Rates



How to find plans like Plan 5

- The regional Blues and provider-owned locals tend to be best (UHC may be best among nationals)
- Beware of plans with large networks they can't monitor/incentivize best practices
- If they aren't monitoring their event rates, they can't control them
- The best DM

Agenda

- Who am I? Why am I here?
- Why your program results may not be valid
 - Back by popular demand, planes on the ground analogy
 - Examples of mistakes driven by pre-post
- How to Measure validly using utilization rates
 - Real world examples and interesting findings



Interesting findings from followup

- Your asthmatics get admitted to the hospital when they could be sent home
- Your HCC Scores/RAF may not correlate with how sick your seniors really are, in Days/1000
 Leaving millions on the table
- Your angioplasties probably don't reduce your MIs and angina

At what rate do your asthmatics get admitted when They show up in the ER?





Insights from this data

- 40% variation
 - Probably correlates with other decisions to admit, way beyond just asthma
- Both health plans with lowest asthma ER/IP rate also had lowest admit rate from the ER
 - One is being studied as a "best practice" in many areas



RAFs and Days/1000

	RAF	Days/1000 (Acute Care)	Ratio (low is good)
Plan 1	0.91	1850	2032
Plan 2	1.05	1675	1595
Plan 3	1.12	1579	1409
Plan 4	0.93	1884	2025
DMPC Disease Management Purchasing Consortium Advisory Council			

Insights from RAF Analysis

- Two plans are "best practice"
 - Do specific things with specific vendors
 - Per 10,000 Medicare lives, do about \$5-million better!



Angioplasty Rate vs. MIs and Angina (one health plan – typical of others)



Possible insights if analysis holds true

• In addition to "unwarranted variation" which Wennberg has found, there is also no incremental impact of angioplasties on MIs or angina as cardiologists do more of them



Next Steps

- MEASURE event rates—this is what you are trying to impact
- DO NOT track events in the "managed population." Some events occur outside that population. They all must be tracked to determine if a reduction is real or Regression to the Mean
- STOP wasting money on actuaries this is not actuarial science. It's biostatistics and common sense





Purchasing Consortium Advisory Council



15-second shameless plug

- You can do everything here on your own but it's way easier with a DMPC Membership and the DMPC database for comparison
- "Join the Consortium or the terrorists win." George W. Bush

